North American Report

Dyslipidemia Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working

 Breaking News
  • No posts were found

Dyslipidemia Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working

October 11
19:00 2021
Dyslipidemia Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working
DelveInsight Business Research LLP
DelveInsight’s “Dyslipidemia – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Dyslipidemia, historical and forecasted epidemiology as well as the Dyslipidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Dyslipidemia – Market Insights, Epidemiology, and Market Forecast-2030”.

DelveInsight’s “Dyslipidemia – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Dyslipidemia, historical and forecasted epidemiology as well as the Dyslipidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Dyslipidemia Market Report:

  • According to the CDC, in 2015–2016, in the US, more than about 12% (29 million) of adults age 20 and older had total cholesterol higher than 240 mg/dL (95 million had it >200mg/dL), and more than 18% had high-density lipoprotein (HDL, or good) cholesterol levels less than 40 mg/dL. It also states that 7% of US children and adolescents ages 6 to 19 have high total cholesterol.

  • In Europe, EURIKA study, a total of 1591 patients (20.8%) were classified as having high TG levels (≥ 2.3 mmol/l), 1691 (22.1%) had low HDL-C levels (men < 1.0 mmol/l, women < 1.3 mmol/l), and 759 (9.9%) had both high TG and low HDL-C levels. 

Key benefits of the report:

  1. Dyslipidemia market report covers a descriptive overview and comprehensive insight of the Dyslipidemia Epidemiology and Dyslipidemia  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

  2. The Dyslipidemia market report provides insights on the current and emerging therapies.

  3. Dyslipidemia market report provides a global historical and forecasted market covering drug outreach in 7MM.

  4. The Dyslipidemia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Dyslipidemia market.

Got queries? Click here to know more about the Dyslipidemia Market Landscape.

Dyslipidemia Overview

Dyslipidemia is a condition caused by the abnormal fluctuation in the levels of cholesterol as well as lipoproteins such as High-Density Lipoprotein (HDL) and Low-Level Lipoprotein (LDL). Besides tagging them as an important component of the living cells, their existence in escalated levels can increase the risk of getting a heart attack or any other major health issue.

Dyslipidemia Market 

The dynamics of the Dyslipidemia market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Pfizer, Arrowhead Pharmaceuticals, NeuroBo Pharmaceuticals, Eli Lilly and Company, AstraZeneca, and others during the forecasted period 2018-2030.

Learn more by requesting for sample @ Dyslipidemia Market Landscape 

Dyslipidemia Pipeline Therapies and Key Companies 

  • ARO-ANG3: Arrowhead Pharmaceuticals

  • Vupanorsen: Pfizer And TIMI Study Group

  • Gemcabene: NeuroBo Pharmaceuticals

  • AZD8233: AstraZeneca And Parexel

  • LY3475766: Eli Lilly and Company

Dyslipidemia Market Drivers 

  • Increasing global geriatric population 

  • Increase in the prevalence of lifestyle-related and cardiovascular disorders

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Dyslipidemia Patient Share (%) Overview at a Glance

5. Dyslipidemia Market Overview at a Glance

6. Dyslipidemia Disease Background and Overview

7. Dyslipidemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Dyslipidemia 

9. Dyslipidemia Current Treatment and Medical Practices

10. Unmet Needs

11. Dyslipidemia Emerging Therapies

12. Dyslipidemia Market Outlook

13. Country-Wise Dyslipidemia Market Analysis (2018–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Dyslipidemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/